A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC) - Fottner, C; Apostolidis, L; Ferrata, M (J Clin Oncol, 2019)
et al.